Cor Vasa 2003, 44(4):212-219
MORE - MOexipril and REgression of left ventricle hypertrophy in combination therapy. A multicentric, open-label clinical trial
- 1 II. interní klinika
- 2 I. interní-kardioangiologická klinika, Fakultní nemocnice u sv. Anny, Brno, Česká republika
In a nationwide multicentric clinical trial, 420 hypertensive patients were treated, by 40 physicians across the country, by combination therapy using moexipril plus another basic antihypertensive agent of the classes of diuretics, beta-blockers, or calcium-channel blockers. The ACE inhibitor moexipril was added to established therapy in cases of uncontrolled blood pressure, and where blood pressure on existing therapy was greater 140/90 mm Hg.
Moexipril was added in 304 (72.3%) patients monotherapy to a double combination, in 101 (24%) cases to a double combination to form a triple combination, and, in 15 (3.6%) to a triple combination to produce a quadruple combination.
Blood pressure decreased from 161.43 ± 12.84/96,72 ± 7.74 to 135.87 ± 9.98/82.36 ± 5.83 mm Hg (p < 0.0001), heart rate declined from 73.08 ± 9.87 to 69.80 ± 7.91 beats per minute (p < 0.0001), and left ventricle mass fell from 263.24 ± 94.69 g to 246.71 ± 89.08 g (p < 0.0001). A trend toward a greater effect on blood pressure and heart rate seemed to be associated with a combination of moexipril plus a diuretic compared with moexipril plus a beta-blocker, and more marked modulation of left ventricular mass by moexipril plus a diuretic compared with moexipril plus a calcium-channel blocker.
Treatment was associated with a minimum of side effects, with 2 patients (0.5%) discontinuing participation because of dry cough; there was no case of clinically significant hyperkalemia, or angioedema.
Keywords: Hypertension; Moexipril; Combination therapy; Left ventricular hypertrophy
Published: April 1, 2003 Show citation